Opinion Review
Copyright ©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6759-6768
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6759
Figure 1
Figure 1 Semaglutide-mechanisms of action with potential benefits for metabolically associated fatty liver disease/non-alcoholic fatty liver disease patients with increased hepatic and extrahepatic (cardiovascular) risk. FFA: Free fatty acids.